

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/194,889	08/23/1999	LILI FENG	TSRI540.1	3717	
75	7590 05/06/2004			EXAMINER	
THE SCRIPPS RESEARCVH INSTITUTE			SAOUD, CHRISTINE J		
OFFICE OF PATENT COUNSEL TPC-8 10550 NORTH TORREY PINES ROAD LA JOLLA, CA 92037			ART UNIT	PAPER NUMBER	
			1647		
			DATE MAILED: 05/06/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/194,889	FENG ET AL.			
Office Action Summary	Examiner	Art Unit			
	Christine J. Saoud	1647			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
1) Responsive to communication(s) filed on <u>17 Fe</u> 2a) This action is FINAL . 2b) This 3) Since this application is in condition for allower closed in accordance with the practice under E	action is non-final. nce except for formal matters, pr				
Disposition of Claims					
4) Claim(s) 1-3,6,7,18,20-24 and 26-31 is/are per 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) 1-3,6,7,18,20-24 and 26-31 is/are rejected to. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or are subject to restriction and/or are subjected to by the Examine 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the or Replacement drawing sheet(s) including the correction	vn from consideration. ected. r election requirement. r. epted or b) objected to by the drawing(s) be held in abeyance. Se	e 37 CFR 1.85(a).			
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:				

Art Unit: 1647

DETAILED ACTION

In view of the Brief filed on 17 February 2004, PROSECUTION IS HEREBY REOPENED. A new ground of rejection is set forth below.

To avoid abandonment of the application, appellant must exercise one of the following two options:

- (1) file a reply under 37 CFR 1.111 (if this Office action is non-final) or a reply under 37 CFR 1.113 (if this Office action is final); or,
 - (2) request reinstatement of the appeal.

If reinstatement of the appeal is requested, such request must be accompanied by a supplemental appeal brief, but no new amendments, affidavits (37 CFR 1.130, 1.131 or 1.132) or other evidence are permitted. See 37 CFR 1.193(b)(2).

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000.

Art Unit: 1647

Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 1-3, and 6-7 are rejected under 35 U.S.C. 102(e) as being anticipated by Campfield et al. (U.S. Pat. No. 6,025,325).

The instant claims encompass administration of an OB receptor agonist (or OB protein) to an animal (claim 1). Claim 2 requires the agonist to be human OB protein and claim 3 requires the amount to be in the range of 1 microgram per kilogram to about 50 micrograms per kilogram body weight. The limitations of "conferring resistance to endotoxic shock", the shock "occurs in sepsis" and "occurs in systemic inflammatory reponse syndrome" are intended use recitations and these limitations would still be met by the administration of leptin for another purpose. The art will be applied accordingly.

Campfield et al. teach compositions of OB protein from mice and humans (see at least column 12-13). Campfield et al. further teach the administration of human OB to animals in the range of 1 microgram per kilogram to about 50 micrograms per kilogram body weight (see at least example 16 at column 27). Since the method steps meet the limitations of the claims, the invention of Campfield et al. would be expected to also meet the limitations of conferring resistance to endotoxic shock as recited in the claims, regardless of the nature of the shock, absent evidence to the contrary.

Rejections which are maintained

Claims 18, 20-24 and 27 stand rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way to

Art Unit: 1647

enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention for the reasons of record in the previous Office actions.

Claims 18, 20-24, 26, 28-31 stand rejected under 35. U.S.C. 103(a) as being unpatentable over Grunfeld et al. (J. Clin. Invest. 97(9): 2152-2157, 1996) for the reasons of record in the previous Office actions.

The previous rejection of claims 1-3 and 6-7 for lack of enablement is withdrawn in light of the new ground of rejection above.

Conclusion

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christine J. Saoud whose telephone number is 571-272-0891. The examiner can normally be reached on mttr, 8:00-2:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz can be reached on 571-272-0887. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1647

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

CHRISTINE J. SAOUD PRIMARY EXAMINER

SUPERVISORY PATENT EXAMINED TECHNOLOGY CENTER 1600